Table 2. Demographic and clinicopathologic characteristics of 110,120 non-Hispanic white and Asian cases with first primary female invasive breast cancer with complete data from the California Cancer Registry 2000–2013*.
| White (n = 93,089) | Pacific Islander (n = 543) | Southeast Asian (n = 3,886) | Indian Continent (n=1,175) | Chinese (n = 3,796) | Japanese (n = 1,736) | Filipino (n = 4,868) | Korean (n = 1,027) | Total (n = 110,120) | All Asian/ Pacific Islander Combined (n = 17,031) | |
|---|---|---|---|---|---|---|---|---|---|---|
| Mean age (yr)† | 61.56 ± 13.46 | 56.56 ± 12.70 | 54.04 ± 12.43 | 54.15 ± 13.68 | 55.68 ± 12.13 | 61.12 ± 14.48 | 56.48 ± 12.07 | 53.82 ± 12.14 | 60.68 ± 13.54 | 55.90 ± 12.95 |
| Year of diagnosis | ||||||||||
| 2000-2006 | 46,774 (50.2) | 206 (37.9) | 1,550 (39.9) | 463 (39.4) | 1,642 (43.3) | 861 (49.6) | 2,053 (42.2) | 457 (44.5) | 54,006 (49.0) | 7,232 (42.5) |
| 2007-2013 | 46,315 (49.8) | 337 (62.1) | 2,336 (60.1) | 712 (60.6) | 2,154 (56.7) | 875 (50.4) | 2,815 (57.8) | 570 (55.5) | 56,114 (51.0) | 9,799 (57.5) |
| Age (yr) | ||||||||||
| ≤ 45 | 11,143 (12.0) | 112 (20.6) | 1,039 (26.7) | 362 (30.8) | 882 (23.2) | 260 (15.0) | 942 (19.4) | 271 (26.4) | 15,011 (13.6) | 3,868 (22.7) |
| 46-69 | 54,861 (58.9) | 336 (61.9) | 2,394 (61.6) | 642 (54.6) | 2,271 (59.8) | 911 (52.5) | 3,197 (65.7) | 640 (62.3) | 65,252 (59.3) | 10,391 (61.0) |
| ≥ 70 | 27,085 (29.1) | 95 (17.5) | 453 (11.7) | 171 (14.6) | 643 (16.9) | 565 (32.5) | 729 (15.0) | 116 (11.3) | 29,857 (27.1) | 2,772 (16.3) |
| Status | ||||||||||
| Alive | 71,762 (77.1) | 437 (80.5) | 3,411 (87.8) | 1,011 (86.0) | 3,268 (86.1) | 1,428 (82.3) | 4,157 (85.4) | 881 (85.8) | 86,355 (78.4) | 14,593 (85.7) |
| Death due to breast cancer | 9,455 (10.2) | 65 (12.0) | 309 (8.0) | 112 (9.5) | 348 (9.2) | 121 (7.0) | 499 (10.3) | 102 (9.9) | 11,011 (10.0) | 1,556 (9.1) |
| Death due to other cause | 11,872 (12.8) | 41 (7.6) | 166 (4.3) | 52 (4.4) | 180 (4.7) | 187 (10.8) | 212 (4.4) | 44 (4.3) | 12,754 (11.6) | 882 (5.2) |
| AJCC stage | ||||||||||
| I | 47,489 (51.0) | 231 (42.5) | 1,772 (45.6) | 450 (38.3) | 1,850 (48.7) | 943 (54.3) | 2,029 (41.7) | 429 (41.8) | 55,193 (50.1) | 7,704 (45.2) |
| II | 34,173 (36.7) | 209 (38.5) | 1,613 (41.5) | 544 (46.3) | 1,495 (39.4) | 637 (36.7) | 2,091 (43.0) | 448 (43.6) | 41,210 (37.4) | 7,037 (41.3) |
| III | 8,838 (9.5) | 75 (13.8) | 414 (10.7) | 140 (11.9) | 354 (9.3) | 125 (7.2) | 569 (11.7) | 125 (12.2) | 10,640 (9.7) | 1,802 (10.6) |
| IV | 2,589 (2.8) | 28 (5.2) | 87 (2.2) | 41 (3.5) | 97 (2.6) | 31 (1.8) | 179 (3.7) | 25 (2.4) | 3,077 (2.8) | 488 (2.9) |
| SES | ||||||||||
| 1-low | 6,119 (6.6) | 63 (11.6) | 350 (9.0) | 65 (5.5) | 181 (4.8) | 74 (4.3) | 384 (7.9) | 89 (8.7) | 7,325 (6.7) | 1,206 (7.1) |
| 2 | 12,739 (13.7) | 111 (20.4) | 633 (16.3) | 129 (11.0) | 318 (8.4) | 201 (11.6) | 891 (18.3) | 157 (15.3) | 15,179 (13.8) | 2,440 (14.3) |
| 3 | 18,647 (20.0) | 124 (22.8) | 702 (18.1) | 182 (15.5) | 593 (15.6) | 315 (18.1) | 1,195 (24.5) | 170 (16.6) | 21,928 (19.9) | 3,281 (19.3) |
| 4 | 18,647 (26.1) | 142 (26.2) | 956 (24.6) | 302 (25.7) | 1,034 (27.2) | 495 (28.5) | 1,408 (28.9) | 242 (23.6) | 28,912 (26.3) | 4,579 (26.9) |
| 5-high | 24,333 (33.6) | 103 (19.0) | 1,245 (32.0) | 497 (42.3) | 1,670 (44.0) | 651 (37.5) | 990 (20.3) | 369 (35.9) | 36,776 (33.4) | 5,525 (32.4) |
| Tumor grade | ||||||||||
| I | 23,903 (25.7) | 80 (14.7) | 704 (18.1) | 201 (17.1) | 734 (19.3) | 432 (24.9) | 803 (16.5) | 171 (16.7) | 27,028 (24.5) | 3,125 (18.3) |
| II | 40,576 (43.6) | 242 (44.6) | 1,697 (43.7) | 465 (39.6) | 1,652 (43.5) | 793 (45.7) | 2,122 (43.6) | 391 (38.1) | 47,938 (43.5) | 7,362 (43.2) |
| III | 27,457 (29.5) | 215 (39.6) | 1,448 (37.3) | 497 (42.3) | 1,344 (35.4) | 495 (28.5) | 1,880 (38.6) | 445 (43.3) | 33,791 (30.7) | 6,324 (37.1) |
| IV (undifferentiated) | 1,143 (1.2) | 6 (1.1) | 37 (1.0) | 12 (1.0) | 66 (1.7) | 16 (0.9) | 63 (1.3) | 20 (1.9) | 1,363 (1.2) | 220 (1.3) |
| Chemotherapy | ||||||||||
| Yes | 56,233 (60.4) | 257 (47.3) | 1,915 (49.3) | 496 (42.2) | 1,955 (51.5) | 1,060 (61.1) | 2,231 (45.8) | 487 (47.4) | 64,634 (58.7) | 8,401 (49.3) |
| No | 36,856 (39.6) | 286 (52.7) | 1,971 (50.7) | 679 (57.8) | 1,841 (48.5) | 676 (38.9) | 2,637 (54.2) | 540 (52.6) | 45,486 (41.3) | 8,630 (50.7) |
| Endocrine therapy | ||||||||||
| Yes | 50,552 (54.3) | 269 (49.5) | 2,167 (55.8) | 621 (52.9) | 1,958 (51.6) | 942 (54.3) | 2,646 (54.4) | 658 (64.1) | 59,813 (54.3) | 9,261 (54.4) |
| No | 42,537 (45.7) | 274 (50.5) | 1,719 (44.2) | 554 (47.1) | 1,838 (48.4) | 794 (45.7) | 2,222 (45.6) | 369 (35.9) | 50,307 (45.7) | 7,770 (45.6) |
| Radiation therapy | ||||||||||
| Yes | 42,671 (54.2) | 250 (54.0) | 2,046 (47.3) | 514 (56.3) | 1,834 (51.7) | 822 (52.6) | 2,591 (46.8) | 540 (47.4) | 51,268 (53.4) | 8,597 (49.5) |
| No | 50,418 (45.8) | 293 (46.0) | 1,840 (52.7) | 661 (43.7) | 1,962 (48.3) | 914 (47.4) | 2,277 (53.2) | 487 (52.6) | 58,852 (46.6) | 8,434 (50.5) |
| Surgery | ||||||||||
| None | 2,288 (2.5) | 27 (5.0) | 103 (2.7) | 45 (3.8) | 89 (2.3) | 35 (2.0) | 168 (3.5) | 40 (3.9) | 2,795 (2.5) | 507 (3.0) |
| Lumpectomy | 57,053 (61.3) | 288 (53.0) | 1,913 (49.2) | 603 (51.3) | 1,967 (51.8) | 1,023 (58.9) | 2,192 (45.0) | 513 (50.0) | 65,552 (59.5) | 8,499 (49.9) |
| Mastectomy | 33,748 (36.3) | 228 (42.0) | 1,870 (48.1) | 527 (44.9) | 1,740 (45.8) | 678 (39.1) | 2,508 (51.5) | 474 (46.2) | 41,773 (37.9) | 8,025 (47.1) |
| Tumor size (mm) | ||||||||||
| < 5.0 | 5,928 (6.4) | 30 (5.5) | 259 (6.7) | 68 (5.8) | 276 (7.3) | 139 (8.0) | 309 (6.3) | 62 (6.0) | 7,071 (6.4) | 1,143 (6.7) |
| ≥ 5.0, < 10.0 | 17,319 (18.6) | 64 (11.8) | 609 (15.7) | 141 (12.0) | 608 (16.0) | 305 (17.6) | 628 (12.9) | 122 (11.9) | 19,796 (18.0) | 2,477 (14.5) |
| ≥ 10.0, < 20.0 | 35,857 (38.5) | 188 (34.6) | 1,363 (35.1) | 389 (33.1) | 1,424 (37.5) | 716 (41.2) | 1,645 (33.8) | 392 (38.2) | 41,974 (38.1) | 6,117 (35.9) |
| ≥ 20.0, < 50.0 | 26,752 (28.7) | 192 (35.4) | 1,315 (33.8) | 455 (38.7) | 1,204 (31.7) | 469 (27.0) | 1,814 (37.3) | 357 (34.8) | 32,558 (29.6) | 5,806 (34.1) |
| ≥ 50.0 | 7,233 (7.8) | 69 (12.7) | 340 (8.7) | 122 (10.4) | 284 (7.5) | 107 (6.2) | 472 (9.7) | 94 (9.2) | 8,721 (7.9) | 1,488 (8.7) |
| ER/PR/HER2 subtype | ||||||||||
| ER+/PR+/HER2- | 57,159 (61.4) | 327 (60.2) | 2,147 (55.2) | 644 (54.8) | 2,171 (57.2) | 1,072 (61.8) | 2,689 (55.2) | 507 (49.4) | 66,716 (60.6) | 9,557 (56.1) |
| ER+/PR+/HER2+ | 7,860 (8.4) | 62 (11.4) | 409 (10.5) | 116 (9.9) | 397 (10.5) | 167 (9.6) | 606 (12.4) | 140 (13.6) | 9,757 (8.9) | 1,897 (11.1) |
| ER+/PR-/HER2- | 8,877 (9.5) | 32 (5.9) | 339 (8.7) | 70 (6.0) | 300 (7.9) | 166 (9.6) | 398 (8.2) | 56 (5.5) | 10,238 (9.3) | 1,361 (8.0) |
| ER+/PR-/HER2+ | 2,759 (3.0) | 13 (2.4) | 143 (3.7) | 30 (2.6) | 142 (3.7) | 54 (3.1) | 185 (3.8) | 40 (3.9) | 3,366 (3.1) | 607 (3.6) |
| ER-/PR+/HER2- | 652 (0.7) | 5 (0.9) | 25 (0.6) | 14 (1.2) | 30 (0.8) | 11 (0.6) | 36 (0.7) | 11 (1.1) | 784 (0.7) | 132 (0.8) |
| ER-/PR+/HER2+ | 267 (0.3) | 0 | 25 (0.6) | 4 (0.3) | 10 (0.3) | 6 (0.3) | 22 (0.5) | 4 (0.4) | 338 (0.3) | 71 (0.4) |
| ER-/PR-/HER2- | 10,650 (11.4) | 59 (10.9) | 465 (12.0) | 204 (17.4) | 402 (10.6) | 173 (10.0) | 435 (8.9) | 160 (15.6) | 12,548 (11.4) | 1,898 (11.1) |
| ER-/PR-/HER2+ | 4,865 (5.2) | 45 (8.3) | 333 (8.6) | 93 (7.9) | 344 (9.1) | 87 (5.0) | 497 (10.2) | 109 (10.6) | 6,373 (5.8) | 1,508 (8.9) |
Data are presented as number (%).
AJCC=American Joint Committee on Cancer; SES=socioeconomic status; ER=estrogen receptor; PR=progesterone receptor; HER2=human epidermal growth factor receptor 2.
*Percents are of total cases within a race/ethnicity; †Mean±SD.